可测量残留病灶检测对多发性骨髓瘤缓解深度、持续时间及变化方向的临床评估价值
单中心回顾性分析234例多发性骨髓瘤患者(新诊断159例、复发难治75例),采用免疫球蛋白基因二代测序检测可测量残留病灶(MRD,灵敏度10⁻⁶)。新诊断和复发难治队列中,达到MRD阴性者中位无进展生存期均更优;系列监测可将新诊断患者分为克隆持续下降、稳定或增加三类,预后不同。
要点
- 新诊断队列达MRD 10⁻⁵者中位PFS 87个月,未达者32个月(P < .001)。
- 复发难治队列达MRD 10⁻⁵者中位PFS 42个月,未达者17个月(P < .01)。
- 新诊断患者按MRD动态分三组,A、B组中位PFS未达到,C组55个月(P < .001)。
核心结论
- 这项将MRD检测用于常规临床实践的回顾性评估证实,MRD是新诊断和复发难治多发性骨髓瘤的重要预后标志物,并支持其作为未来临床试验终点及临床决策依据。
研究设计与样本
- 单中心回顾性评估,纳入234例多发性骨髓瘤患者,其中新诊断159例、复发难治75例。
- MRD采用免疫球蛋白基因二代测序检测,灵敏度为10⁻⁶。
主要发现
- 新诊断队列中40%达MRD 10⁻⁶阴性、59%达10⁻⁵阴性;达10⁻⁵者中位PFS 87个月 vs 未达者32个月(P < .001)。
- 复发难治队列中36%达MRD 10⁻⁶阴性、47%达10⁻⁵阴性;达10⁻⁵者中位PFS 42个月 vs 未达者17个月(P < .01)。
- 系列MRD监测将新诊断患者分为三组:A组≥3次MRD 10⁻⁶阴性样本,B组可检测但克隆数持续下降,C组克隆数稳定或增加≥1 log;A、B组中位PFS未达到,C组55个月(P < .001)。
关键数值与推荐
- 新诊断队列达MRD 10⁻⁶阴性者40%,达10⁻⁵阴性者59%。
- 复发难治队列达MRD 10⁻⁶阴性者36%,达10⁻⁵阴性者47%。
- 新诊断队列MRD 10⁻⁵阳性 vs 阴性中位PFS:87个月 vs 32个月(P < .001)。
- 复发难治队列MRD 10⁻⁵阳性 vs 阴性中位PFS:42个月 vs 17个月(P < .01)。
- 新诊断患者按MRD动态分组中位PFS:A组未达到、B组未达到、C组55个月(P < .001)。
临床怎么用
- 作者认为MRD可作为新诊断和复发难治多发性骨髓瘤的预后标志物,并支持其用于未来临床试验终点及临床决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Few clinical studies have reported results of measurable residual disease (MRD) assessments performed as part of routine practice. Herein we present our single-institution experience assessing MRD in 234 multiple myeloma (MM) patients (newly diagnosed [NDMM = 159] and relapsed [RRMM = 75]). We describe the impact of depth, duration, and direction of response on prognosis. MRD assessments were performed by next-generation sequencing of immunoglobulin genes with a sensitivity of 10-6. Those achieving MRD negativity at 10-6, as well as 10-5, had superior median progression-free survival (PFS). In the NDMM cohort, 40% of the patients achieved MRD negativity at 10-6 and 59% at 10-5. Median PFS in the NDMM cohort was superior in those achieving MRD at 10-5 vs <10-5 (PFS: 87 months vs 32 months; P < .001). In the RRMM cohort, 36% achieved MRD negativity at 10-6 and 47% at 10-5. Median PFS was superior for the RRMM achieving MRD at 10-5 vs <10-5 (PFS: 42 months vs 17 months; P < .01). Serial MRD monitoring identified 3 categories of NDMM patients: (A) patients with ≥3 MRD 10-6 negative samples, (B) patients with detectable but continuously declining clonal numbers, and (C) patients with stable or increasing clonal number (≥1 log). PFS was superior in groups A and B vs C (median PFS not reached [NR], NR, 55 respectively; P < .001). This retrospective evaluation of MRD used as part of clinical care validates MRD as an important prognostic marker in NDMM and RRMM and supports its use as an endpoint in future clinical trials as well as for clinical decision making.
引用
- Martinez-Lopez J, Wong SW, Shah N, et al. Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma. Blood Adv. 2020. PMID: 32706892. doi:10.1182/bloodadvances.2020002037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。